Key result
Recombinant human GH administration resulted in similar adipose tissue responsiveness between abdominally obese and normal weight postmenopausal women.
Why the study?
Does an intravenous bolus of recombinant human GH alter lipolysis differently in abdominally obese versus normal weight postmenopausal women?
RCT (n=16)
randomly administered
Does an intravenous bolus of recombinant human GH alter lipolysis differently in abdominally obese versus normal weight postmenopausal women?
Hyposomatotropism in abdominally obese individuals is not compensated by increased adipose tissue responsiveness to GH, leading to blunted lipolysis.
Answers are grounded in this paper and cite their sources.
Similar GH responsiveness in obese and lean postmenopausal women indicates uncompensated hyposomatotropism; extends evidence for blunted lipolysis without adipose adaptation.
Abdominal obesity is associated with reduced 24-h plasma GH concentrations. It is unclear whether hyposomatotropism in abdominally obese humans is compensated by up-regulation of GH receptor sensitivity or causes less biological effect in target tissues. We, therefore, determined the responsiveness of adipose tissue to the lipolytic action of GH in abdominally obese (OB) and normal weight (NW) postmenopausal women. An iv bolus of recombinant human GH or placebo was randomly administered to eight NW [body mass index (BMI): 22.2 +/- 1.6 kg/m(2)] and eight abdominally OB (BMI: 32.1 +/- 2.6 kg/m(2)) women. Lipolysis was measured by infusion of D5-glycerol and modeled as a function of plasma GH concentrations to describe adipose tissue responsiveness. Similar plasma GH concentration peaks ( approximately 20 mU/liter) were achieved by GH injection in both groups. During placebo conditions, the average plasma GH level was significantly lower in OB compared with NW women (0.74 +/- 0.52 vs. 2.08 +/- 1.18 mU/liter, P = 0.023). Adipose tissue responsiveness, expressed as glycerol rate of appearance per kilogram of fat mass per unit plasma GH concentration was not different in both groups (NW: 1.06, OB: 0.68, P > 0.05). These results suggest that hyposomatotropism in abdominally obese individuals is not compensated by increased adipose tissue responsiveness to GH bio-action and, therefore, blunts lipolysis in these individuals.
No takes yet. Share an insight, caveat, or question.
Buijs et al. (2002) conducted an RCT in Abdominal obesity (n=16). Recombinant human GH vs. Placebo was evaluated on Adipose tissue responsiveness (glycerol rate of appearance per kilogram of fat mass per unit plasma GH concentration) (p=>0.05). Recombinant human GH administration resulted in similar adipose tissue responsiveness between abdominally obese and normal weight postmenopausal women.
Synapse has enriched 10 related papers. Consider them for comparative context: